Loading clinical trials...
Loading clinical trials...
A Phase 2b, Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
Conditions
Interventions
AZD1722
Placebo
Locations
41
United States
Research Site
Downey, California, United States
Research Site
Los Angeles, California, United States
Research Site
Sacramento, California, United States
Research Site
Whittier, California, United States
Research Site
Denver, Colorado, United States
Research Site
Pembroke Pines, Florida, United States
Start Date
March 1, 2014
Primary Completion Date
November 1, 2014
Completion Date
November 1, 2014
Last Updated
September 14, 2020
NCT06933472
NCT03573089
NCT00506441
NCT00542815
NCT05085275
NCT04456803
Lead Sponsor
Ardelyx
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions